Overcoming Barriers to Equitable Care in Hepatocellular Carcinoma: Integrating New Evidence Into Clinical Practice

Released On
December 15, 2022

Expires On
December 15, 2023

Media Type

Completion Time
60 minutes



Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Postgraduate Institute for Medicine and RME Collaborative.

This online program is recorded content from the live session at Oncology Congress and co-supported by independent medical education grants from AbbVie, Inc.; Astellas; AstraZeneca Pharmaceuticals; Bayer HealthCare Pharmaceuticals, Inc.; Eisai, Inc.; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; and Seagen. This activity is supported independent medical education grants from AstraZeneca Pharmaceuticals; Eisai, Inc.; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

Program Overview

In rural and underserved communities, the incidence of hepatocellular carcinoma (HCC) continues to rise steadily, especially among Blacks and non-Hispanic Whites. Unique challenges in these areas such as oncology workforce shortages and transportation barriers exacerbate the problem, making residents more likely to be diagnosed with HCC at a late stage and less likely to receive treatment compared with those in urban areas. In this activity, expert faculty will review current and emerging treatment options and strategies for individualizing therapy for patients with unresectable disease. Evidence-based methods to reduce disparities and improve access to HCC care in rural and underserved settings will also be discussed.

This enduring activity is a recorded session from Oncology Congress that took place on September 24, 2022.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Apply clinical evidence on the efficacy and safety of systemic therapies for unresectable hepatocellular carcinoma (HCC) into clinical practice
  • Develop personalized treatment plans that consider individual patient and disease characteristics as well as clinical profiles of therapeutic options for unresectable HCC
  • Implement evidence-based strategies for reducing disparities in HCC care access and treatment in rural and underserved settings




Ghassan K. Abou-Alfa, MD, MBA

Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY


Sucharu (Chris) Prakash, MD

Oncologist & Regional Medical Director
Texas Oncology - Paris
Paris, TX

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine and RME Collaborative adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Postgraduate Institute for Medicine requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies (commercial interests). All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to Postgraduate Institute for Medicine policy. Postgraduate Institute for Medicine is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:



Ghassan K. Abou-Alfa, MD, MBA, has disclosed the following relevant financial relationships: research/grant support from Arcus Biosciences, AstraZeneca Pharmaceuticals, BioNTech, BMS, Celgene Corporation, Flatiron Health, Genentech, Inc./Roche, Genoscience Pharma, Incyte Corporation, Polaris Pharmaceuticals, Inc., Puma Biotechnology, Inc., QED Therapeutics, Silenseed, and Yiviva; consultant for Adicet Bio, Inc., Alnylam Pharmaceuticals, AstraZeneca Pharmaceuticals, Autem Therapeutics, BeiGene, Berry Genomics, Boehringer Ingelheim, Celgene Corporation, Cend Therapeutics, CytomX Therapeutics, Eisai, Inc., Eli Lilly and Company, Exelixis, Inc., Flatiron Health, Genentech, Inc./Roche, Genoscience Pharma, Helio Genomics, Helsinn Group, Incyte Corporation, Ipsen, Merck & Co., Inc., Nerviano Medical Sciences, NewBridge Pharmaceuticals, Novartis Pharmaceuticals Corporation, QED Therapeutics, RedHill Biopharma, Rafael Pharmaceuticals, Inc. (now Cornerstone Pharmaceuticals, Inc.), Servier Pharmaceuticals, Silenseed, Sobi, Vector Pharma, and Yiviva.

Sucharu (Chris) Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer

The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CME credit, participants must:

  1. Read the CME/CE information, including learning objectives and disclosure statements.
  2. Complete the pre-test.
  3. View the online activity.
  4. Complete the post-test and evaluation form.

A post-test score of 67% or higher is required to obtain credit. Your certificate will be made available for immediate download.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

©RME Collaborative, a division of Talem Health, LLC 2022. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.


Internet activity.

Fee Information

There is no fee for this educational activity.

Contact Information

General Questions
For general information or questions about this activity, please contact RME Collaborative at 800-913-9370 or cme@cmeruralhealth.com.

Accreditation Support
For questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine at inquiries@pimed.com.